

**APPENDIX A****Corrected Section of Non-Compliant Amendment****Listing of Claims:**

1-9 (Cancelled)

10. (Presently Amended) A method of inhibiting tumor growth in a mammal comprising administering to said mammal a compound which inhibits expression of alpha-ketoglutarate-dependent dioxygenase aspartyl (asparaginyl) beta-hydroxylase (AAH), wherein said compound is a AAH antisense nucleic acid comprising a sequence which is complementary to a 5' AAH regulatory sequence of SEQ ID NO:3, said nucleic acid comprising consisting of between 10-50 nucleotides, inclusive, in length and wherein said tumor overexpresses AAH compared to a normal noncancerous cell.

11. (Cancelled).

12. (Cancelled).

13. (Originally Filed) The method of claim 10, wherein said tumor is derived from endodermal tissue.

14. (Originally Filed) The method of claim 10, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.

15. (Originally Filed) The method of claim 10, wherein said tumor is a CNS tumor.

16-38 (Cancelled).

39. (Previously Presented) The method of claim 10, wherein said tumor is a glioblastoma.

APPLICANTS: Wands et al.  
SERIAL NUMBER: 09/436,184

40. (Previously Presented) The method of claim 10, wherein said tumor is a neuroblastoma.

41. (Previously Presented) The method of claim 10, wherein said tumor is a cholangiocarcinoma.

42. (Previously Presented) The method of claim 10, wherein said tumor is a hepatocellular carcinoma.

43. (Presently Amended) A method of inhibiting tumor growth in a mammal comprising administering to said mammal a HAAH antisense nucleic acid, wherein said nucleic acid comprises a sequence which is complementary to a 5' portion of an AAH coding sequence of SEQ ID NO:2 and comprises the initiating ATG methionine-encoding codon of said SEQ ID NO:3, said nucleic acid comprising consisting of between 10-50 nucleotides, inclusive, in length and wherein said tumor overexpresses AAH compared to a normal noncancerous cell.

44. (Previously Presented) The method of claim 43, wherein said tumor is derived from endodermal tissue.

45. (Previously Presented) The method of claim 43, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile duct.

46. (Previously Presented) The method of claim 43, wherein said tumor is a CNS tumor.

APPLICANTS: Wands et al.  
SERIAL NUMBER: 09/436,184

47. (Previously Presented) The method of claim 43, wherein said tumor is a glioblastoma.

48. (Previously Presented) The method of claim 43, wherein said tumor is a neuroblastoma.

49. (Previously Presented) The method of claim 43, wherein said tumor is a cholangiocarcinoma.

50. (Previously Presented) The method of claim 43, wherein said tumor is a hepatocellular carcinoma.

51.- 71. (Canceled)

72. (Newly Added) The method of claim 10, wherein the length of said antisense nucleic acid consists of between 10-20 nucleotides, inclusive.

73. (Newly Added) The method of claim 43, wherein the length of said antisense nucleic acid consists of between 10-20 nucleotides, inclusive.